137 related articles for article (PubMed ID: 12203803)
1. Soluble Tie-2 receptor levels independently predict locoregional recurrence in head and neck squamous cell carcinoma.
Homer JJ; Greenman J; Drevs J; Marme D; Stafford ND
Head Neck; 2002 Aug; 24(8):773-8. PubMed ID: 12203803
[TBL] [Abstract][Full Text] [Related]
2. Soluble CD44 is a potential marker for the early detection of head and neck cancer.
Franzmann EJ; Reategui EP; Pedroso F; Pernas FG; Karakullukcu BM; Carraway KL; Hamilton K; Singal R; Goodwin WJ
Cancer Epidemiol Biomarkers Prev; 2007 Jul; 16(7):1348-55. PubMed ID: 17627000
[TBL] [Abstract][Full Text] [Related]
3. Serum hepatocyte growth factor as a marker of tumor activity in head and neck squamous cell carcinoma.
Kim CH; Lee JS; Kang SO; Bae JH; Hong SP; Kahng H
Oral Oncol; 2007 Nov; 43(10):1021-5. PubMed ID: 17306605
[TBL] [Abstract][Full Text] [Related]
4. Soluble interleukin-2 receptor serum level as a predictor of locoregional control and survival for patients with head and neck carcinoma: results of a multivariate prospective study.
Tartour E; Deneux L; Mosseri V; Jaulerry C; Brunin F; Point D; Validire P; Dubray B; Fridman WH; Rodriguez J
Cancer; 1997 Apr; 79(7):1401-8. PubMed ID: 9083163
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of soluble CD44v6 as a potential serum marker for head and neck squamous cell carcinoma.
Van Hal NL; Van Dongen GA; Ten Brink CB; Heider KH; Rech-Weichselbraun I; Snow GB; Brakenhoff RH
Clin Cancer Res; 1999 Nov; 5(11):3534-41. PubMed ID: 10589769
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of soluble adhesion molecules CD44 (CD44st, CD44v5, CD44v6), ICAM-1, and VCAM-1 as tumor markers in head and neck cancer.
Kawano T; Yanoma S; Nakamura Y; Shiono O; Kokatu T; Kubota A; Furukawa M; Tsukuda M
Am J Otolaryngol; 2005; 26(5):308-13. PubMed ID: 16137528
[TBL] [Abstract][Full Text] [Related]
7. Serum concentrations of interleukin-8, vascular endothelial growth factor, and epidermal growth factor receptor in patients with squamous cell cancer of the head and neck.
Gokhale AS; Haddad RI; Cavacini LA; Wirth L; Weeks L; Hallar M; Faucher J; Posner MR
Oral Oncol; 2005 Jan; 41(1):70-6. PubMed ID: 15598588
[TBL] [Abstract][Full Text] [Related]
8. Serum protein expression predicts recurrence in patients with early-stage lung cancer after resection.
D'Amico TA; Brooks KR; Joshi MB; Conlon D; Herndon J; Petersen RP; Harpole DH
Ann Thorac Surg; 2006 Jun; 81(6):1982-7; discussion 1987. PubMed ID: 16731117
[TBL] [Abstract][Full Text] [Related]
9. High serum soluble E-selectin levels are associated with postoperative haematogenic recurrence in esophageal squamous cell carcinoma patients.
Shimada Y; Maeda M; Watanabe G; Imamura M
Oncol Rep; 2003; 10(4):991-5. PubMed ID: 12792758
[TBL] [Abstract][Full Text] [Related]
10. Serum levels of interleukin-6 in patients with primary head and neck squamous cell carcinoma.
Riedel F; Zaiss I; Herzog D; Götte K; Naim R; Hörmann K
Anticancer Res; 2005; 25(4):2761-5. PubMed ID: 16080523
[TBL] [Abstract][Full Text] [Related]
11. Plasma osteopontin is an independent prognostic marker for head and neck cancers.
Petrik D; Lavori PW; Cao H; Zhu Y; Wong P; Christofferson E; Kaplan MJ; Pinto HA; Sutphin P; Koong AC; Giaccia AJ; Le QT
J Clin Oncol; 2006 Nov; 24(33):5291-7. PubMed ID: 17114663
[TBL] [Abstract][Full Text] [Related]
12. The significance of Tenascin-C serum level as tumor marker in squamous cell carcinoma of the head and neck.
Pauli C; Stieber P; Schmitt UM; Andratschke M; Hoffmann K; Wollenberg B
Anticancer Res; 2002; 22(5):3093-7. PubMed ID: 12530049
[TBL] [Abstract][Full Text] [Related]
13. Salivary soluble CD44: a potential molecular marker for head and neck cancer.
Franzmann EJ; Reategui EP; Carraway KL; Hamilton KL; Weed DT; Goodwin WJ
Cancer Epidemiol Biomarkers Prev; 2005 Mar; 14(3):735-9. PubMed ID: 15767360
[TBL] [Abstract][Full Text] [Related]
14. Tissue inhibitor of matrix metalloproteinase-1 is prognostic in head and neck squamous cell carcinoma: comparison of the circulating and tissue immunoreactive protein.
Ruokolainen H; Pääkkö P; Turpeenniemi-Hujanen T
Clin Cancer Res; 2005 May; 11(9):3257-64. PubMed ID: 15867221
[TBL] [Abstract][Full Text] [Related]
15. Serum levels of folate, homocysteine, and vitamin B12 in head and neck squamous cell carcinoma and in laryngeal leukoplakia.
Almadori G; Bussu F; Galli J; Cadoni G; Zappacosta B; Persichilli S; Minucci A; Giardina B; Maurizi M
Cancer; 2005 Jan; 103(2):284-92. PubMed ID: 15593092
[TBL] [Abstract][Full Text] [Related]
16. The platelet-derived growth factor receptor as a target for vascular endothelial growth factor-mediated anti-angiogenetic therapy in head and neck cancer.
Bran B; Bran G; Hörmann K; Riedel F
Int J Oncol; 2009 Jan; 34(1):255-61. PubMed ID: 19082496
[TBL] [Abstract][Full Text] [Related]
17. Serum protein profile analysis following definitive treatment in patients with head and neck squamous cell carcinoma.
Gourin CG; Moretz WH; Weinberger PM; Xia ZS; Liu Z; Terris DJ; Adam BL
Arch Otolaryngol Head Neck Surg; 2007 Nov; 133(11):1125-30. PubMed ID: 18025317
[TBL] [Abstract][Full Text] [Related]
18. Elevated serum vascular endothelial growth factor and decreased survival in advanced laryngeal carcinoma.
Teknos TN; Cox C; Yoo S; Chepeha DB; Wolf GT; Bradford CR; Carey TE; Fisher SG
Head Neck; 2002 Nov; 24(11):1004-11. PubMed ID: 12410536
[TBL] [Abstract][Full Text] [Related]
19. Circulating levels of vascular endothelial growth factor in patients with oral squamous cell carcinoma.
Shang ZJ; Li JR; Li ZB
Int J Oral Maxillofac Surg; 2002 Oct; 31(5):495-8. PubMed ID: 12418564
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-6 predicts recurrence and survival among head and neck cancer patients.
Duffy SA; Taylor JM; Terrell JE; Islam M; Li Y; Fowler KE; Wolf GT; Teknos TN
Cancer; 2008 Aug; 113(4):750-7. PubMed ID: 18536030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
